<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997798</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYY-BC-001</org_study_id>
    <nct_id>NCT04997798</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Dalpiciclib in Combination With Letrozole and Trastuzumab Plus Pyrotinib in Early ER+ HER2+ Breast Cancer</brief_title>
  <official_title>Phase II Open-label, Multicentre, Exploratory Trial of Neoadjuvant Dalpiciclib in Combination With Letrozole and Trastuzumab Plus Pyrotinib in Early ER+ HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label, multicenter trial. The study assesses the treatment of&#xD;
      patients with ER-positive /HER2 positive early breast cancer with neoadjuvant Dalpiciclib in&#xD;
      Combination With Letrozole and Trastuzumab plus pyrotinib. Patients were treated with&#xD;
      intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) and oral pyrotinib&#xD;
      (400 mg po QD, Q3W) for six cycles plus oral Dalpiciclib (150 mg QD x 21 Q4W) and oral&#xD;
      letrozole (2.5 mg po QD for 20 weeks). The primary endpoints was pathological complete&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response (pCR)</measure>
    <time_frame>at surgery</time_frame>
    <description>Assess the rate of pathological complete response (pCR) defined as ypT0-ypTis ypN0 at surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial measures of Ki67</measure>
    <time_frame>baseline before therapy, 2 weeks after and at surgery</time_frame>
    <description>Changes in Ki67 scores from baseline before therapy, 2 weeks after and then at surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>Tumour assessments will be performed by ultrasound and mammography at screening (prior to start of treatment), and before surgery, an expected average of 24 weeks</time_frame>
    <description>Defined as the number of patients with partial or complete response according to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Estrogen Receptor Positive Tumor</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dalpiciclib in combination with letrozole and trastuzumab plus pyrotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) and oral pyrotinib (400 mg po QD, Q3W) for six cycles plus oral Dalpiciclib (150 mg QD x 21 Q4W) and oral Letrozole (2.5 mg po QD for 20 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Pyrotinib Dalpiciclib Letrozole</intervention_name>
    <description>Neoadjuvant Study of Dalpiciclib in Combination With Letrozole and Trastuzumab plus pyrotinib in early ER+ HER2+ Breast Cancer</description>
    <arm_group_label>Dalpiciclib in combination with letrozole and trastuzumab plus pyrotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 Years to 75 Years&#xD;
&#xD;
          -  Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer, staging criteria is&#xD;
             to be based on AJCC 7.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Primary tumor must have positive estrogen receptor (ER) ≥10%&#xD;
&#xD;
          -  Primary tumor must be HER2-positive (IHC 3+ or FISH/CISH amplification)&#xD;
&#xD;
          -  Baseline LVEF ≥50% measured by Echocardiography (preferred) or MUGA scan&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
          -  Written Informed Consent (IC) must be signed and dated by the patient and the&#xD;
             Investigator prior to randomization.&#xD;
&#xD;
          -  Baseline corrected QT interval (QTcF) &lt; 480 ms&#xD;
&#xD;
          -  All patients must be female.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Evidence of bilateral invasive breast cancer or metastatic disease&#xD;
&#xD;
          -  Received any prior treatment for primary invasive breast cancer&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Abnormal baseline hematological values:&#xD;
&#xD;
          -  Abnormal baseline liver function, bilirubin, creatinine and/or INR (international&#xD;
             normalized ratio)&#xD;
&#xD;
          -  Subjects with known infection with HIV, HBV, HCV&#xD;
&#xD;
          -  Other investigational drugs while on study&#xD;
&#xD;
          -  Severe or uncontrolled hypertension, history of congestive heart failure or severe&#xD;
             coronary arterial disease.&#xD;
&#xD;
          -  Subjects assessed by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

